Regression of Multiple Melanocytic Nevi in Two Patients on Nivolumab for Metastatic Melanoma

Gloria Baeza-Hernández; Ricardo Francisco Rubio-Aguilera; Anastasia Alejandra Garrido-Ríos; Helena Álvarez-Garrido; Cristina Martínez-Morán; Jesús Borbujo

doi:10.5826/dpc.1301a22

Regression of Multiple Melanocytic Nevi in Two Patients on Nivolumab for Metastatic Melanoma

Authors

Gloria Baeza-Hernández Department of Dermatology. Hospital Universitario de Fuenlabrada, Madrid, Spain
Ricardo Francisco Rubio-Aguilera Department of Dermatology. Hospital Universitario de Fuenlabrada, Madrid, Spain
Anastasia Alejandra Garrido-Ríos Department of Dermatology. Hospital Universitario de Fuenlabrada, Madrid, Spain
Helena Álvarez-Garrido Department of Dermatology. Hospital Universitario de Fuenlabrada, Madrid, Spain
Cristina Martínez-Morán Department of Dermatology. Hospital Universitario de Fuenlabrada, Madrid, Spain
Jesús Borbujo Department of Dermatology. Hospital Universitario de Fuenlabrada, Madrid, Spain

Keywords:

nivolumab, regression, melanocytic nevi, melanoma, dermoscopy

References

Navarrete-Dechent C, Cordova M, Postow MA, et al. Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy. JAMA Dermatology. 2019;155(3):347. DOI:10.1001/jamadermatol.2018.3688. PMID: 30624578. PMCID: PMC6440283.

Farinazzo E, Zelin E, Agozzino M, et al. Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma. Melanoma Res. 2021;31(6):582-585. DOI:10.1097/CMR.0000000000000776. PMID: 34433200.

Zhao CY, Hwang SJE, Wakade D, Carlos G, Anforth R, Fernández-Peñas P. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. Australas J Dermatol. 2017;58(4):292-298. DOI:10.1111/ajd.12645. PMID: 28707403.

Wolner ZJ, Marghoob AA, Pulitzer MP, Postow MA, Marchetti MA. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol. 2018;178(1):265-269. DOI:10.1111/bjd.15354. PMID: 28132411. PMCID: PMC5533648.

Mauzo SH, Tetzlaff MT, Nelson K, et al. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. 2019;58(9):1045-1052. DOI:10.1111/ijd.13833. PMID: 29152725.

Vazquez B, Velasco R, Martin JM, Gonzalez I, Ramon MD. Regression of multiple melanocytic nevi associated with nivolumab treatment for metastatic melanoma. Int J Dermatol. 2019;58(11):1331-1333. DOI:10.1111/ijd.14340. PMID: 30536371.

Nakamura Y, Fujino T, Kagamu H, et al. Induction of immune reaction in benign melanocytic nevi without halo during nivolumab therapy in a patient with melanoma. JAMA Dermatology. 2017;153(8):832-834. DOI:10.1001/jamadermatol.2017.0615. PMID: 28492864.

Nanda JK, Dusza SW, Navarrete-Dechent C, Liopyris K, Marghoob AA, Marchetti MA. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors. JAMA Dermatology. 2021;157(1):79. DOI:10.1001/jamadermatol.2020.3671. PMID: 32936222. PMCID: PMC7495326.

Lallas A, Apalla Z, Kyrgidis A, et al. Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring. J Am Acad Dermatol. 2020;82(2):398-406. DOI:10.1016/j.jaad.2019.08.074. PMID: 31499156.